Phase I Exploratory Study of IV Formulation of Panobinostat in Combination with Bortezomib in Relapsed/Refractory Multiple Myeloma Patients: Effect On Serum PTH and Gene Expression Profiling (GEP) Studies
Maurizio Zangari(University of Arkansas for Medical Sciences), Fenghuang Zhan(Winthrop Rockefeller Foundation), Tamara Berno(University of Padua), Ye Yang(Yangtze University), Jessica Kohan(University of Utah), Mohamed E. Salama(The University of Texas at San Antonio Health Science Center), Wen Zhou(Academy of Medical Sciences), Karen Pena(Huntsman Cancer Institute), Jiliang Xia(Central South University), Leanne Lujan(Huntsman Cancer Institute), He Wang(Qilu University of Technology), Yi Zhou(University of Utah), Xin Zhan(Vanderbilt University), Giampaolo Talamo(University of Perugia)
Cited by 2
Related Papers
Frequent Engagement of the Classical and Alternative NF-κB Pathways by Diverse Genetic Abnormalities in Multiple Myeloma
|Cancer Cell|2007|949
MYC Drives Progression of Small Cell Lung Cancer to a Variant Neuroendocrine Subtype with Vulnerability to Aurora Kinase Inhibition
|Cancer Cell|2017|619
Alternative splicing and cancer: a systematic review
|Signal Transduction and Targeted Therapy|2021|489